Internal Systems Limited (ISL)

Belkins
ISL deliver fully managed pro-active outsourced IT Support covering an organisations complete IT environment, including desktops, servers, mobile devices, Anti Virus and Backup. Our service is 24/7 delivering excellence and maximum uptime for your business.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

news image

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More

DENOVO BIOPHARMA ANNOUNCES BREAKTHROUGH DISCOVERY OF A NOVEL GENETIC BIOMARKER FOR DB104 (LIAFENSINE) FOR DEPRESSION

BioSpace | March 12, 2020

news image

Denovo Biopharma LLC LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has successfully discovered a novel genetic biomarker associated with DB104 response to treat depression using its proprietary biomarker discovery platform. DB104 was licensed from Albany Molecular Research, Inc. following its return from Bristol-Myers Squibb, who had conducted two phase 2b clinical trials in treatment-resistant depression with this first-in-class triple reuptak...

Read More

RESEARCH

POSTERA ANNOUNCES $260M MULTI-TARGET STRATEGIC AI LAB COLLABORATION WITH PFIZER

PostEra | January 12, 2022

news image

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced the expansion of the company's existing strategic collaboration with Pfizer. The expanded multi-target research program will establish an AI Lab where PostEra and Pfizer jointly advance multiple drug discovery programs with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI Lab will leverage novel machine learning for medicinal chemistry built upon Pfizer's da...

Read More

XYLYX BIO LAUNCHES SPECIALIZED CONTRACT R&D SERVICES THAT SUPPORT IMPROVED ASSESSMENT OF ANTIFIBROTIC DRUG CANDIDATE EFFICACY

Xylyx Bio | September 30, 2020

news image

Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Approximately 40% of development costs are associated with preclinical studies, yet 80% of drug candidates fail before reaching Phase I trials, largely due to lack of translatability of efficacy data to hum...

Read More
news image

CELL AND GENE THERAPY

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More
news image

DENOVO BIOPHARMA ANNOUNCES BREAKTHROUGH DISCOVERY OF A NOVEL GENETIC BIOMARKER FOR DB104 (LIAFENSINE) FOR DEPRESSION

BioSpace | March 12, 2020

Denovo Biopharma LLC LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has successfully discovered a novel genetic biomarker associated with DB104 response to treat depression using its proprietary biomarker discovery platform. DB104 was licensed from Albany Molecular Research, Inc. following its return from Bristol-Myers Squibb, who had conducted two phase 2b clinical trials in treatment-resistant depression with this first-in-class triple reuptak...

Read More
news image

RESEARCH

POSTERA ANNOUNCES $260M MULTI-TARGET STRATEGIC AI LAB COLLABORATION WITH PFIZER

PostEra | January 12, 2022

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced the expansion of the company's existing strategic collaboration with Pfizer. The expanded multi-target research program will establish an AI Lab where PostEra and Pfizer jointly advance multiple drug discovery programs with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI Lab will leverage novel machine learning for medicinal chemistry built upon Pfizer's da...

Read More
news image

XYLYX BIO LAUNCHES SPECIALIZED CONTRACT R&D SERVICES THAT SUPPORT IMPROVED ASSESSMENT OF ANTIFIBROTIC DRUG CANDIDATE EFFICACY

Xylyx Bio | September 30, 2020

Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Approximately 40% of development costs are associated with preclinical studies, yet 80% of drug candidates fail before reaching Phase I trials, largely due to lack of translatability of efficacy data to hum...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us